Inovio Cuts Q2 Losses by 27%
Inovio Pharmaceuticals (NASDAQ:INO), a biotechnology company developing DNA medicines, released its second-quarter fiscal 2025 earnings on August 12, 2025. The key news from this release is the continued focus on advancing its lead candidate, INO-3107 for recurrent respiratory papillomatosis (RRP), toward regulatory submission, alongside diligent cost management. GAAP net loss was $23.5 million, or $0.61 per share (GAAP). Analysts had expected minimal revenue of $0.01 million, but no GAAP revenue was reported. Lower operating expenses contributed to a reduced loss compared to the prior-year period. Overall, the quarter reflected operational focus and clinical momentum but continued the pattern of no recurring revenue and ongoing net losses.
Source: Analyst estimates for the quarter provided by FactSet.
Inovio Pharmaceuticals is a biotechnology company that designs and develops DNA medicines. Its business centers on discovering products that can treat cancers, infectious diseases, and rare disorders by delivering synthetically designed DNA directly into patients. The company is advancing its main therapy, INO-3107, which targets recurrent respiratory papillomatosis, a rare disease characterized by benign growths in the airways, often requiring frequent surgeries as the current standard of care.
Source Fool.com
